


IRBLLEIDA EXTERNAL SEMINAR

DR. ISRAEL FERNÁNDEZ

Group Leader of Stroke Pharmacogenomics and Genetics laboratory,

Santa Creu i Sant Pau Research Institute, Barcelona

Genetics and epigenetics analysis in stroke. be useful to find drug targets?



Host by: GLÒRIA ARQUÉ garque@irblleida.cat



IRBLLEIDA SEMINAR TYPE: EXTERN

ABSTRACT

Stroke is the second cause of death in Spain, first in women and one the main causes of disability in adults. There are treatments to decrease stroke occurrence, however there is a lack of neuroprotection drugs to improve the disability rates after stroke. Genome Wide studies are unbiased techniques that can help to find new drug targets for potential neuroprotection drugs. In this talk we will explain the last results of these studies involving thousands of stroke patients and how these techniques can answer clinical questions that only expensive clinical trials can resolve.

ISRAEL FERNÁNDEZ

The biologist Israel Fernández Cadenas is the principal investigator of the Stroke Pharmacogenomics and Genetics laboratory of the Santa Creu i Sant Pau Research Institute composed by seven members.

He is an expert in stroke genetics and epigenetics with more than 100 articles. Part of his post-doctoral training has been carried out at the Wellcome Trust Center for Human Genetics in Oxford and at the GH Servievsky center at the University of Columbia, NY.

Actively participates in several consortia for the genetic study of complex diseases. He is currently the Vice-chair of the ISGC consortium (International Stroke Genetics Consortium) (www.strokegenetics.com) and the Chair of the Genestroke (Spanish Consortium for the Genetic Study of Ictus) (www.genestroke.com) being one of the founding members.

